Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | TSHR | P16473 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5908888 | 0.87 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2ALMNAHTT | |
| SCHEMBL5909264 | 0.81 | L3MBTL1 (0.48) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL5909304 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL5908883 | 0.78 | L3MBTL1 (0.46) | ALDH1A1TSHRMEN1KMT2AUSP2 | |
| SCHEMBL10724385 | 0.77 | ALDH1A1 (1.00) | ALDH1A1TSHRMEN1KMT2AUSP2 | |
| SCHEMBL5908976 | 0.76 | AKR1C3 (0.47) | ALDH1A1TSHRHTTTP53MAPT | |
| SCHEMBL9565911 | 0.75 | ALDH1A1 (0.81) | ALDH1A1TSHRMEN1KMT2AUSP2 | |
| SCHEMBL13406708 | 0.74 | ALDH1A1 (0.63) | ALDH1A1TSHRMEN1KMT2AUSP2 | |
| SCHEMBL5909090 | 0.73 | ALDH1A1 (0.59) | ALDH1A1TSHRHTTTP53NPC1 | |
| SCHEMBL27295608 | 0.71 | ALDH1A1 (0.76) | ALDH1A1TSHRMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | HAVIV FORTUNA | 2006-02-09 | — | — | US | disclosed |
| EP-1494672-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| WO-2003086398-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | ALDH1A1 206/4885TSHR 3978/4885MEN1 2787/4885 |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | FLT4, KDR, FLT1 | ALDH1A1 424/4885TSHR 3670/4885MEN1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.